

Update: Formulary Changes

Effective June 03, 2019, Breo Ellipta® (fluticasone/vilanterol) inhalers will be removed from the Keystone First and Keystone First Community HealthChoices drug formulary.

Members/Participants currently receiving any of the products listed below will require a new prescription for an alternative product before **August 05, 2019**. Members/Participants for whom it is not medically advisable to change therapy will require prior authorization to continue to receive coverage for the formulary changed products.

Formulary Removals	
Product List	Alternative Product(s)
Breo Ellipta® (fluticasone/vilanterol) 100-25mcg and 200-25mcg inhalers	<ul style="list-style-type: none">generic Airduo™ Respiclick® (fluticasone/salmeterol)generic Advair Diskus® (fluticasone propion/salmeterol)

Additional prior authorization criteria may apply. Please refer to most recent drug formulary and prior authorization information available on the Plans' websites:

Keystone First: www.keystonefirstpa.com→Providers→Pharmacy Services

Keystone First Community HealthChoices: www.keystonefirstchc.com→Providers→Pharmacy Services

If you have any questions regarding this notice, please contact:

Keystone First Pharmacy Services at 1-800-588-6767

Keystone First Community HealthChoices Pharmacy Services 1-866-907-7088

April 23, 2019